Paper Details

  1. Home
  2. Paper Details

Gepants for the treatment of migraine.

Author: MartellettiPaolo, NegroAndrea

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Calcitonin gene-related peptide (CGRP) receptor antagonists, a new class of drugs, show promise for the acute treatment of migraine. They are primarily developed to address the limitations of triptans, the current standard of care, which include incomplete pain relief, high rates of headache recurrence, and side effects. CGRP is a key target for migraine treatments currently under development.
Paper Details　
Original Abstract of the Article :
Migraine is the most common of all neurological disorders. A breakthrough in migraine treatment emerged in the early nineties with the introduction of 5-HT1B/D receptor agonists called triptans. Triptans are used as the standard of care for acute migraine; however, they have significant limitations ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/13543784.2019.1618830

データ提供：米国国立医学図書館（NLM）

Gepants: A New Era in Migraine Treatment

Migraine, a debilitating neurological disorder, can significantly impact a person's quality of life. While triptans have been the standard of care for acute migraine, they have limitations in terms of effectiveness, side effects, and contraindications. This study explores the potential of gepants, a new class of drugs that target the calcitonin gene-related peptide (CGRP) receptor, as a novel treatment for acute migraine.

Gepants: A Promising New Approach to Migraine

Gepants, CGRP receptor antagonists, are a class of drugs specifically developed for the acute treatment of migraine. CGRP is a key player in the migraine pathway, and blocking its receptor has shown promise in reducing migraine pain and severity. The study provides an overview of gepants, highlighting their potential as a new therapeutic option for migraine. This research is like a refreshing breeze in the desert of migraine treatment, bringing new hope for relief from this debilitating condition.

What Does This Mean for Migraine Sufferers?

This research provides a glimmer of hope for migraine sufferers. Gepants, a new class of drugs, offer a potential alternative to triptans, with the possibility of improved efficacy and fewer side effects. This is a significant development in the fight against migraine, and it represents a potential shift in the landscape of migraine treatment.

Dr.Camel's Conclusion

The desert of migraine research is vast and challenging, but this research offers a promising oasis. Gepants, a new class of migraine medications, hold great potential for improving the lives of migraine sufferers. It is a reminder that we must continue to explore new frontiers in medical research to find effective solutions for even the most complex medical conditions.

Date :
  1. Date Completed 2019-06-27
  2. Date Revised 2019-10-15
Further Info :

Pubmed ID

31081399

DOI: Digital Object Identifier

10.1080/13543784.2019.1618830

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.